Emerging treatment approaches for myeloma-related bone disease.

about

Pathogenesis of bone disease in multiple myeloma: from bench to bedside.Semaphorin 4D correlates with increased bone resorption, hypercalcemia, and disease stage in newly diagnosed patients with multiple myeloma.

P2860

Q47734632-6FD7C0FA-1947-4CCE-B7A2-5D638DCC753A Q55397591-F5260881-8BEF-4C0A-85D0-5D242D37AE36

P2860

Emerging treatment approaches for myeloma-related bone disease.

Item

http://www.wikidata.org/entity/Q39090721

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Emerging treatment approaches for myeloma-related bone disease.

@en

Emerging treatment approaches for myeloma-related bone disease.

@nl

type

Item

label

Emerging treatment approaches for myeloma-related bone disease.

@en

Emerging treatment approaches for myeloma-related bone disease.

@nl

prefLabel

Emerging treatment approaches for myeloma-related bone disease.

@en

Emerging treatment approaches for myeloma-related bone disease.

@nl

P1476

Emerging treatment approaches for myeloma-related bone disease.

@en

P2093

Evangelos Terpos

http://www.w3.org/2001/XMLSchema#string

P2860

Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST)

Novel mechanism of Wnt signalling inhibition mediated by Dickkopf-1 interaction with LRP6/Arrow

A novel role for CCL3 (MIP-1α) in myeloma-induced bone disease via osteocalcin downregulation and inhibition of osteoblast function

Osteocyte control of bone formation via sclerostin, a novel BMP antagonist

Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation

Osteoprotegerin: a novel secreted protein involved in the regulation of bone density

Progression of interleukin-2 (IL-2)-dependent rat T cell lymphoma lines to IL-2-independent growth following activation of a gene (Gfi-1) encoding a novel zinc finger protein

Activins and activin antagonists in hepatocellular carcinoma

A high-affinity fully human anti-IL-6 mAb, 1339, for the treatment of multiple myeloma

Selective inhibitors of the osteoblast proteasome stimulate bone formation in vivo and in vitro

P304

217-228

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1080/17474086.2017.1283213

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Meletios A. Dimopoulos

Efstathios Kastritis

Maria Gavriatopoulou

P577

2017-01-17T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28092987

http://www.w3.org/2001/XMLSchema#string

Emerging treatment approaches for myeloma-related bone disease.

about

P2860

P2860

Emerging treatment approaches for myeloma-related bone disease.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698